Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
COSMO Pharmaceuticals N.V. ( (CH:COPN) ) has shared an update.
Cosmo Pharmaceuticals N.V. unveiled its ambitious vision for 2030 at the Investor Day 2025, aiming for EUR 480 million in recurring revenues and a 40% EBITDA margin. The company plans to leverage AI-driven growth and innovation, focusing on expanding its core business and digital AI platforms. This strategic roadmap is expected to position Cosmo as a significant player in the future of healthcare, creating value for patients, partners, and shareholders.
The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF113.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.
More about COSMO Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V. is a life-science company specializing in MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). The company designs, develops, and manufactures advanced solutions to address critical medical needs, aiming to improve the standard of care. Cosmo’s technologies are trusted by leading global pharma and MedTech companies, reaching patients and healthcare providers worldwide. Founded in 1997, the company is headquartered in Dublin, Ireland, with offices in San Diego, USA, and several locations in Italy.
Average Trading Volume: 24,500
Current Market Cap: CHF958.1M
For an in-depth examination of COPN stock, go to TipRanks’ Overview page.